Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRiMe: PK of Antituberculosis Drugs in Breastfeeding Women
NCT07069582Phase 1Completed
- Sponsor
- McGill University Health Centre
- Start
- Jun 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rifampicin, isoniazid, levofloxacin, rifapentine and bedaquiline in Tuberculosis (TB) (6 arms), sponsored by McGill University Health Centre. Primary endpoints: Area under the concentration-time curve from 0 to 24 hours and Peak concentration at Day 1. Started Jun 2026; status: completed.
02
Drugs
rifampicinisoniazidlevofloxacinrifapentinebedaquiline
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07069582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07069582.